Full Press Release Details
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit.
RARE
Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
Key Takeaway: Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
Price reaction · baseline $78.22 (2021-10-22 close) · 1 other RARE headline(s) in the window, move may be shared
day 0 close · peak
+1.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia